NAS:MYOK (USA) Also trade in: Germany

MyoKardia Inc

$ 49.39 0 (0%)
Volume: 243,727 Avg Vol (1m): 581,637
Market Cap $: 2.28 Bil Enterprise Value $: 1.72 Bil
P/E (TTM): 0.00 P/B: 3.28
Earnings Power Value 1.12
Net Current Asset Value 13.13
Tangible Book 15.11
Projected FCF 0
Median P/S Value 23.71
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
67.90% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
MYOK: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.91
Equity-to-Asset ranked higher than
83.75% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
MYOK: 0.91
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.8, Med: 0.82, Max: 0.91
Current: 0.91
-0.8
0.91
Interest Coverage No Debt
Interest Coverage ranked higher than
60.20% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
MYOK: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 43.81
DISTRESS
GREY
SAFE
Beneish M-Score -1.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -519.88%
WACC 10.14%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -282.47
Operating Margin ranked lower than
59.85% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
MYOK: -282.47
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -512.73, Med: -219.47, Max: -25.1
Current: -282.47
-512.73
-25.1
Net Margin % -260.29
Net Margin ranked lower than
59.22% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
MYOK: -260.29
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -498.25, Med: -201.73, Max: -24.73
Current: -260.29
-498.25
-24.73
ROE % -22.21
ROE ranked higher than
61.78% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
MYOK: -22.21
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -98.99, Med: -26.42, Max: -8.68
Current: -22.21
-98.99
-8.68
ROA % -20.08
ROA ranked higher than
62.45% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
MYOK: -20.08
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -270.04, Med: -25.81, Max: -6.53
Current: -20.08
-270.04
-6.53
ROC (Joel Greenblatt) % -1930.75
ROC (Joel Greenblatt) ranked lower than
65.93% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
MYOK: -1930.75
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1987.03, Med: -803.9, Max: -382.88
Current: -1930.75
-1987.03
-382.88
3-Year Total Revenue Growth Rate 33.20
3-Year Revenue Growth Rate ranked higher than
79.42% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
MYOK: -27.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -27.1, Max: -1.2
Current: -27.1
0
-1.2
3-Year Total EBITDA Growth Rate -48.00
3-Year EBITDA Growth Rate ranked lower than
67.83% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
MYOK: 19
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -20.2, Med: 19, Max: 24.7
Current: 19
-20.2
24.7
3-Year EPS w/o NRI Growth Rate 26.80
3-Year EPS w/o NRI Growth Rate ranked lower than
52.95% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
MYOK: 26.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -4.2, Max: 26.8
Current: 26.8
0
26.8

» MYOK's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MYOK

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:XLRN NAS:EDIT XKRX:095700 NAS:SPPI NAS:RXDX NYSE:CBM NAS:AIMT NAS:ESPR BOM:539268 NAS:SGMO SZSE:002653 SZSE:002287 NAS:CORT NAS:INSM NAS:ARNA NAS:INVA NAS:MDGL XKRX:005250 NAS:IMGN NAS:PTLA
Traded in other countries 9MK.Germany
Address 333 Allerton Avenue, South San Francisco, CA, USA, 94080
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Ratios

Current vs industry vs history
PB Ratio 3.28
PB Ratio ranked lower than
65.59% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
MYOK: 3.28
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.95, Med: 5.02, Max: 11.52
Current: 3.28
1.95
11.52
PS Ratio 69.18
PS Ratio ranked lower than
83.20% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
MYOK: 69.18
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 8, Med: 33.21, Max: 162.61
Current: 69.18
8
162.61
EV-to-EBIT -18.11
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
MYOK: -18.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -55.8, Med: -18.7, Max: -3.1
Current: -18.11
-55.8
-3.1
EV-to-EBITDA -18.44
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
MYOK: -18.44
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -58.9, Med: -19.3, Max: -3.2
Current: -18.44
-58.9
-3.2
EV-to-Revenue 51.13
EV-to-Revenue ranked lower than
78.86% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
MYOK: 51.13
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.9, Med: 28.4, Max: 153.5
Current: 51.13
4.9
153.5
Current Ratio 18.00
Current Ratio ranked higher than
71.88% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
MYOK: 18
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.94, Med: 5.41, Max: 18
Current: 18
0.94
18
Quick Ratio 18.00
Quick Ratio ranked higher than
72.63% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
MYOK: 18
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.94, Med: 5.41, Max: 18
Current: 18
0.94
18

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.40
3-Year Share Buyback Rate ranked lower than
73.98% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
MYOK: -12.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -29.8, Med: -24.2, Max: -12.4
Current: -12.4
-29.8
-12.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.27
Price-to-Tangible-Book ranked lower than
57.72% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
MYOK: 3.27
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.8, Med: 4.75, Max: 8.07
Current: 3.27
2.8
8.07
Price-to-Median-PS-Value 2.08
Price-to-Median-PS-Value ranked lower than
90.41% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
MYOK: 2.08
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.28, Med: 0.97, Max: 3.65
Current: 2.08
0.28
3.65
Earnings Yield (Joel Greenblatt) % -5.52
Earnings Yield (Greenblatt) ranked higher than
64.94% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
MYOK: -5.52
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -32.6, Med: -5.3, Max: -1.8
Current: -5.52
-32.6
-1.8

More Statistics

Revenue (TTM) (Mil) $ 33.56
EPS (TTM) $ -2.19
Beta 1.29
Volatility % 47.63
52-Week Range $ 39.01 - 67.79
Shares Outstanding (Mil) 46.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y